# Daily Iteration Report — 2026-04-11 (Run 22)

## Summary
Validated 3 research paths, processed 2 work queue items, audited 3 gaps, credibility sweep passed, all 39 build scripts green.

## Research Path Validations

### verapamil → T1D: PARTIALLY_VALIDATED
- **Ver-A-T1D** (European RCT, 136 pts, 21 sites, 6 countries): presented EASD Sep 2025. Trend toward beta-cell preservation but **underpowered** — placebo C-peptide decline only 0.09 nmol/L/min (less than anticipated).
- **Pediatric RCT** (PMID:36826844, n=88): 30% higher C-peptide at 52 weeks with verapamil.
- **Adult RCT** (PMID:29988125): improved C-peptide AUC at 3 and 12 months.
- **Ver-A-Long** extension ongoing; 24-month data pending.
- **Rating rationale**: Strong pediatric signal + positive adult trend, but pivotal European trial underpowered. Awaiting 24-month data.

### dapagliflozin → inflammation: VALIDATED
- **Cardiovasc Diabetology 2024**: dapagliflozin reduces systemic inflammation (hsCRP, IL-6) in T2D without HF.
- **Frontiers Cardiovasc Med 2021**: limits NLRP3 inflammasome activation via AMPK/mTOR.
- **Ann Transl Med**: attenuates ROS-NLRP3 axis in steatohepatitis with DM.
- **Mechanism**: SGLT2i → increased circulating ketones → ketones inhibit NLRP3 → reduced IL-1β/IL-18.
- **Rating rationale**: Convergent preclinical and clinical evidence from multiple independent groups.

### NLRP3 inflammasome → inflammation: VALIDATED
- **DAPAN-DIA** (NCT06047262): first large RCT of oral NLRP3 inhibitor (dapansutrile 1000mg BID) in T2D. 300 patients, multicenter, active-recruiting as of Feb 2026.
- MCC950 development halted (hepatotoxicity), but dapansutrile has clean safety across 6 clinical trials.
- **Rating rationale**: Robust mechanistic evidence + dedicated clinical trial in progress.

## Work Queue Items Processed

### COYA 301 Treg Therapy (priority 5)
- Phase 2 Alzheimer's results: 4.93-point ADAS-Cog improvement vs placebo over 21 weeks.
- Significant proinflammatory biomarker reductions, increased anti-inflammatory IL-4.
- Well tolerated, no SAEs.
- **Cross-relevance to diabetes**: Confirms low-dose IL-2 Treg enhancement is clinically viable. Relevant to T1D Treg therapeutic approaches.
- Next check: October 2026 (awaiting single-cell proteomics data 2H 2026).

### PROSPERO CRD420251073207 (priority 5)
- Could not verify this PROSPERO ID via web search — site requires direct database access.
- ID format is consistent with real registrations but **remains unconfirmed**.
- **Action taken**: Flagged as UNVERIFIED in build_gap_synthesis.py (lines 159, 1034).
- Next check: May 2026 (manual verification recommended).

## Gap Audits

### Gap 6: Islet Transplant × Health Equity (GOLD)
- Frontiers in Transplantation 2025 review (PMC11925927) details post-BLA challenges including equity concerns.
- LANTIDRA supply limited to cadaveric islets — no scale-up possible. Celltrans only receives from local OPO.
- UH Cleveland approved Nov 2025, UIC Health active. Facility expansion slow.
- Vertex VX-264 Phase 3 (encapsulated stem-cell islets) could democratize access if approved.
- **Tier: GOLD (unchanged)**

### Gap 7: GWAS/Polygenic × Closed Loop/AP (SILVER)
- PMC11794728 (2025) reviews PRS integration into personalized diabetes care — but focuses on pharmacotherapy, not closed-loop systems.
- Nature Comms 2025: PRS performance is context-dependent (age, sex, comorbidity).
- AI+CGM integration emerging but genetic stratification not yet applied to AP algorithms.
- **Tier: SILVER (unchanged)** — still no bridging publications.

### Gap 9: Gene Therapy × LADA (EXPLORATORY)
- Still no gene therapy trials targeting LADA as of April 2026.
- Cleveland Clinic J Med 2025 and StatPearls 2025 confirm LADA management remains conventional.
- **Tier: EXPLORATORY (unchanged)** — no new evidence.

## Credibility Sweep
- **PMIDs > 42000000**: None found ✓
- **"zero SAEs" / "zero rejection"**: None found ✓
- **"achieves" / "curative"**: 6 instances of "achieves" reviewed — all factual/contextual (e.g., "TTP399 achieves tissue selectivity", "achieves 80% of universal screening's cost-effectiveness"). No overstated preclinical claims. "curative" only in verify_before_deploy.py as a check target. ✓

## Pipeline Status
- **39/39 scripts: [OK]**
- build_gap_synthesis.py file truncation fixed during this run.
- PROSPERO reference annotated as [unverified].

## Git Status
- Commit created locally but **push failed** (no GitHub credentials in sandbox).
- Changes persisted in workspace folder. Push needed on next run with credentials.

## Cumulative Progress
- Papers: 244/244 vetted (100%)
- Research paths validated: 3 new this run (2 VALIDATED, 1 PARTIALLY_VALIDATED)
- Gaps audited: 15/15 current (3 re-audited this run)
- Total runs: 22
